Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Fuji
Healthtrust
Colorcon
Fish and Richardson
McKinsey
Harvard Business School
Citi
US Department of Justice
AstraZeneca

Generated: October 22, 2017

DrugPatentWatch Database Preview

ZERBAXA Drug Profile

« Back to Dashboard

What is the patent landscape for Zerbaxa, and what generic Zerbaxa alternatives are available?

Zerbaxa is a drug marketed by Cubist Pharms Llc and is included in one NDA. There are six patents protecting this drug.

This drug has forty-seven patent family members in twenty-six countries and seven supplementary protection certificates in six countries.

The generic ingredient in ZERBAXA is ceftolozane sulfate; tazobactam sodium. One supplier is listed for this compound. Additional details are available on the ceftolozane sulfate; tazobactam sodium profile page.

Summary for Tradename: ZERBAXA

US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZERBAXA at DailyMed

Pharmacology for Tradename: ZERBAXA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZERBAXA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,044,485Ceftolozane antibiotic compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZERBAXA

Country Document Number Estimated Expiration
Portugal1556389► Subscribe
Luxembourg92943► Subscribe
China1708502► Subscribe
China105392485► Subscribe
Chile2015002755► Subscribe
Australia2014233633► Subscribe
New Zealand631761► Subscribe
Canada2906151► Subscribe
Japan2016517436► Subscribe
China100343260► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZERBAXA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0004France► SubscribePRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
2016 00004Denmark► SubscribePRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
2015000113Germany► SubscribePRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
943Luxembourg► SubscribePRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
2016 00004Denmark► SubscribePRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
2016Austria► SubscribePRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 (MITTEILUNG) 20150922
0793Netherlands► SubscribePRODUCT NAME: CEFTOLOZAAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN IN HET BIJZONDER EEN ZWAVELZUURZOUT; REGISTRATION NO/DATE: EU/1/15/1032 20150922
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
UBS
McKesson
Medtronic
Daiichi Sankyo
Deloitte
US Army
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot